SAN DIEGO – Glenmark Pharmaceuticals Inc. has struck a deal to license a small-molecule cancer candidate from APC Therapeutics Inc., gaining worldwide development and commercialization rights to a compound based on antigen-presenting cell (APC) biology with potential as a monotherapy or in combination with existing therapies, it said.